Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53
The DOI matches its Crossref record; 28 of the 29 references it cites were found in a registry or an index.
Abstract
The gene p53 encodes a transcriptional activator of genes involved in growth arrest, DNA repair and apoptosis. Loss of p53 function contributes to tumour development in vivo. The transcriptional activation function of p53 is inactivated by interaction with the mdm2 gene product. Amplification of mdm2 has been observed in 36% of human sarcomas, indicating that it may represent an alternative mechanism of preventing p53 function in tumour development. To study mdm2 function in vivo, we generated an mdm2 null allele by homologous recombination. Mdm2 null mice are not viable, and further analysis revealed embryonic lethality around implantation. To examine the importance of the interaction of MDM2 with p53 in vivo, we crossed mice heterozygous for mdm2 and p53 and obtained progeny homozygous for both p53 and mdm2 null alleles. Rescue of the mdm2-/- lethality in a p53 null background suggests that a critical in vivo function of MDM2 is the negative regulation of p53 activity.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Mdm2 can recruit HDAC1 to p53 to remove these acetylation marks and allow for p53 ubiquitination and degradation [49] in in vitro and mouse models [47,50].”
From Acetylation: a new target for protein degradation in cancer (2025) · cites this paper as [50]
In the citing paper
“Loss of Mdm2 leads to cell death by apoptosis and embryonic lethality at the blastocyst stage, and this phenotype is completely rescued by concomitant deletion of p53 (Chavez-Reyes, et al., 2003; Jones, et al., 1995; Montes de Oca Luna, et al., 1995).”
From The Mdm network and its regulation of p53 activities: a rheostat of cancer risk (2014) · cites this paper as Montes de Oca Luna, et al., 1995
In the citing paper
“Mouse genetic models strongly suggest that MDM2 and MDMX are the two major p53 antagonists in vivo107,108”
From MDM2, MDMX and p53 in oncogenesis and cancer therapy (2013) · cites this paper as [107]
In the citing paper
“Mouse genetic models strongly suggest that MDM2 and MDMX are the two major p53 antagonists in vivo107,108 and that they exert non-overlapping inhibitory activities towards p53 (Refs 24,109).”
From MDM2, MDMX and p53 in oncogenesis and cancer therapy (2013) · cites this paper as [107]
In the citing paper
“The crucial importance of MDM2 in regulating p53 was demonstrated using Mdm2-null mice, which display very early embryonic lethality (Jones et al., 1995; Montes de Oca Luna et al., 1995).”
From p53 at a glance (2010) · cites this paper as Montes de Oca Luna et al., 1995
Citations
Cites
WAF1, a potential mediator of p53 tumor suppression
El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., & Vogelstein, B. (1993) · Cell · doi:10.1016/0092-8674(93)90500-p · Cited by 8,321
The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases.
Wade Harper, J. (1993) · Cell · doi:10.1016/0092-8674(93)90499-g · Cited by 5,651
Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours
Donehower, L. A., Harvey, M., Slagle, B. L., McArthur, M. J., Montgomery, C. A., Butel, J. S., & Bradley, A. (1992) · Nature · doi:10.1038/356215a0 · Cited by 4,649
Tumor suppressor p53 is a direct transcriptional activator of the human bax gene
Toshiyuki, M., & Reed, J. C. (1995) · Cell · doi:10.1016/0092-8674(95)90412-3 · Cited by 4,063
Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis.
Greenblatt, M. S., Bennett, W. P., Hollstein, M., & Harris, C. C. (1994) · PubMed · Cited by 3,463
Momand, J., Zambetti, G. P., Olson, D. C., George, D., & Levine, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90644-r · Cited by 3,113
Kastan, M. B., Zhan, Q., El-Deiry, W. S., Carrier, F., Jacks, T., Walsh, W. V., Plunkett, B. S., Vogelstein, B., & Fornace, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90593-2 · Cited by 3,047
p53-dependent apoptosis modulates the cytotoxicity of anticancer agents
Lowe, S. W., Ruley, H. E., Jacks, T., & Housman, D. E. (1993) · Cell · doi:10.1016/0092-8674(93)90719-7 · Cited by 2,925
p53 is required for radiation-induced apoptosis in mouse thymocytes
Lowe, S. W., Schmitt, E. M., Smith, S. W., Osborne, B. A., & Jacks, T. (1993) · Nature · doi:10.1038/362847a0 · Cited by 2,864
Thymocyte apoptosis induced by p53-dependent and independent pathways
Clarke, A. R., Purdie, C. A., Harrison, D. J., Morris, R. G., Bird, C. C., Hooper, M. L., & Wyllie, A. H. (1993) · Nature · doi:10.1038/362849a0 · Cited by 2,271
Research works printed but not linked: 1
- Greenblatt, M. S., Bennett, W. P., Hollstein, M. & Harris C. C. Cancer Res. 54, 4855–4878 (1994).
Cited by
Items 201–300 of 1,001
The p53 tumour suppressor gene
Steele, R. J. C., Thompson, A. M., Hall, P. A., & Lane, D. P. (1998) · Journal of British Surgery · doi:10.1046/j.1365-2168.1998.00910.x · Cited by 183
Biological and clinical importance of the p53 tumor suppressor gene
Velculescu, V. E., & El-Deiry, W. S. (1996) · Clinical Chemistry · doi:10.1093/clinchem/42.6.858 · Cited by 180
Inactivation of HAUSP in vivo modulates p53 function.
Kon, N., Kobayashi, Y., Li, M., Brooks, C. L., Ludwig, T., & Gu, W. (2010) · Oncogene · doi:10.1038/onc.2009.427 · Cited by 176
“However, combining a p53-null background with the mdm2 knockout rescues this phenotype, suggesting that Mdm2 is a major negative regulator of p53 (Jones et al., 1995; Montes de Oca Luna et al., 1995).”
Regulating the p53 system through ubiquitination
Yang, Y., Li, C.-C. H., & Weissman, A. M. (2004) · Oncogene · doi:10.1038/sj.onc.1207411 · Cited by 179
“Nevertheless, as is the case for Mdm2, MdmX deficiency leads to embryonic death that is rescued by the loss of p53 (Jones et al., 1995; Montes de Oca Luna et al., 1995; Parant et al., 2001; Finch et al., 2002; Migliorini et al., 2002), indicating that MdmX is also a critical negative regulator of p53 in vivo.”
BackgroundRibosomal protein S14 unties the MDM2–p53 loop upon ribosomal stress
Zhou, X., Hao, Q., Liao, J., Zhang, Q., & Lu, H. (2013) · Oncogene · doi:10.1038/onc.2012.63 · Cited by 176
Targeting Apoptosis Pathways for New Cancer Therapeutics
Bai, L., & Wang, S. (2014) · Annual Review of Medicine · doi:10.1146/annurev-med-010713-141310 · Cited by 176
“For example, deletion of MDM2 in mice is embryonic lethal, which can be rescued by concurrent deletion of p53 (89, 90).”
BackgroundRole of Ubiquitin Ligases and the Proteasome in Oncogenesis: Novel Targets for Anticancer Therapies
Micel, L. N., Tentler, J. J., Smith, P. G., & Eckhardt, G. S. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.0958 · Cited by 176
The Regulation of Multiple p53 Stress Responses is Mediated through MDM2
Hu, W., Feng, Z., & Levine, A. J. (2012) · Genes & Cancer · doi:10.1177/1947601912454734 · Cited by 175
p53-Mediated Repression of Alpha-Fetoprotein Gene Expression by Specific DNA Binding
Lee, K. C., Crowe, A. J., & Barton, M. C. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.2.1279 · Cited by 175
“However, studies of cellular differentiation and p53 function (24, 55, 66, 70, 80), as well as overexpression of p53 in transgenic mice (24) or knockout of its genetic repressor MDM 2 (10), have underscored the importance of maintaining tightly regulated p53 activity during normal development.”
BackgroundRinaldo, C., Prodosmo, A., Mancini, F., Iacovelli, S., Sacchi, A., Moretti, F., & Soddu, S. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.02.008 · Cited by 174
“…To test whether MDM2 is involved in p53-induced HIPK2 degradation, mouse embryo fibroblasts (MEFs) from Mdm2/p53 double-knockout (dKO) mice (Montes de Oca Luna et al., 1995) were transiently transfected with expression vectors carrying EGFP, EGFP-HIPK2, MDM2, or p53 in different combinations.”
MethodThe role of p53-target genes in human cancer
Tokino, T., & Nakamura, Y. (2000) · Critical Reviews in Oncology/Hematology · doi:10.1016/s1040-8428(99)00051-7 · Cited by 174
Shu, Z., Smith, S., Wang, L., Rice, M. C., & Kmiec, E. B. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.12.8686 · Cited by 174
“p53 plays a pivotal role in cell cycle control and apoptosis, and the embryonic lethality caused by mRAD51, BRCA1, and BRCA2 is partially rescued while mdm2-deficient mice are completely rescued in a p53-null background (9, 16, 17, 19).”
BackgroundPhan, J., Li, Z., Kasprzak, A., Li, B., Sebti, S., Guida, W., Schönbrunn, E., & Chen, J. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.073056 · Cited by 173
The regulation of MDM2 oncogene and its impact on human cancers
Zhao, Y., Yu, H., & Hu, W. (2014) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmt147 · Cited by 173
Wu, L., & Levine, A. J. (1997) · Molecular Medicine · doi:10.1007/bf03401691 · Cited by 172
Kodama, T., Takehara, T., Hikita, H., Shimizu, S., Shigekawa, M., Tsunematsu, H., Li, W., Miyagi, T., Hosui, A., Tatsumi, T., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci44957 · Cited by 171
Genotoxic and non-genotoxic pathways of p53 induction
Pluquet, O., & Hainaut, P. (2001) · Cancer Letters · doi:10.1016/s0304-3835(01)00698-x · Cited by 171
The Transactivation Domains of the p53 Protein
Raj, N., & Attardi, L. D. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026047 · Cited by 168
“5–11.5, respectively, because of inappropriate p53-driven apoptosis or cell-cycle arrest in embryos (Jones et al. 1995; Montes de Oca Luna et al. 1995; de Rozieres et al. 2000; Parant et al. 2001; Finch et al. 2002; Migliorini et al. 2002).”
BackgroundInfluentialTargeting Mdm2 and Mdmx in cancer therapy: better living through medicinal chemistry?
Wade, M., & Wahl, G. M. (2009) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-08-0423 · Cited by 170
Blagosklonny, M. V. (2000) · The FASEB Journal · doi:10.1096/fj.99-1078rev · Cited by 170
“degradation because the Mdm-2 knockout is lethal and is corrected by the p53 knockout (33).”
BackgroundChen, J., Ruan, H., Ng, S. M., Gao, C., Soo, H. M., Wu, W., Zhang, Z., Wen, Z., Lane, D. P., & Peng, J. (2005) · Genes & Development · doi:10.1101/gad.1366405 · Cited by 170
“embryos is the likely cause of lethality ( Montes de Oca et al. 1995 ).”
BackgroundMomand, J., & Zambetti, G. P. (1997) · Journal of Cellular Biochemistry · doi:10.1002/(sici)1097-4644(19970301)64:3<343::aid-jcb1>3.0.co;2-v · Cited by 168
The role of ubiquitin modification in the regulation of p53
Hock, A. K., & Vousden, K. H. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2013.05.022 · Cited by 168
ATM-Mediated Phosphorylations Inhibit Mdmx/Mdm2 Stabilization by HAUSP in Favor of p53 Activation
Meulmeester, E., Pereg, Y., Shiloh, Y., & Jochemsen, A. G. (2005) · Cell Cycle · doi:10.4161/cc.4.9.1981 · Cited by 167
Limiting the power of p53 through the ubiquitin proteasome pathway
Pant, V., & Lozano, G. (2014) · Genes & Development · doi:10.1101/gad.247452.114 · Cited by 167
Self-citationGottlieb, E. (1997) · The EMBO Journal · doi:10.1093/emboj/16.6.1381 · Cited by 166
p19ARF targets certain E2F species for degradation
Martelli, F., Hamilton, T., Silver, D. P., Sharpless, N. E., Bardeesy, N., Rokas, M., DePinho, R. A., Livingston, D. M., & Grossman, S. R. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.081061398 · Cited by 166
Koblish, H. K., Zhao, S., Franks, C. F., Donatelli, R. R., Tominovich, R. M., LaFrance, L. V., Leonard, K. A., Gushue, J. M., Parks, D. J., Calvo, R. R., et al. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0199 · Cited by 165
“Thus, the major function of Hdm2 is to suppress p53 function in vivo (14, 15).”
BackgroundThe MDM2 Oncoprotein Binds Specifically to RNA through its RING Finger Domain
Elenbaas, B., Dobbelstein, M., Roth, J., Shenk, T., & Levine, A. J. (1996) · Molecular Medicine · doi:10.1007/bf03401903 · Cited by 164
Hdmx modulates the outcome of p53 activation in human tumor cells
Wade, M., Wong, E. T., Tang, M., Stommel, J. M., & Wahl, G. M. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m605405200 · Cited by 163
Inactivation of the p53-homologue p73 by the mdm2-oncoprotein
Dobbelstein, M., Wienzek, S., König, C., & Roth, J. (1999) · Oncogene · doi:10.1038/sj.onc.1202512 · Cited by 161
“Inhibition of p53 by mdm2 is crucial for the development of the entire organism, since mice lacking the mdm2 gene are not viable unless the p53 gene is missing, too (Jones et al., 1995; Montes de Oca Luna et al., 1995).”
BackgroundVisualization and targeted disruption of protein interactions in living cells
Herce, H. D., Deng, W., Helma, J., Leonhardt, H., & Cardoso, M. C. (2013) · Nature Communications · doi:10.1038/ncomms3660 · Cited by 162
Kawamura, Y., Uchijima, Y., Horike, N., Tonami, K., Nishiyama, K., Amano, T., Asano, T., Kurihara, Y., & Kurihara, H. (2010) · Journal of Clinical Investigation · doi:10.1172/jci42020 · Cited by 162
Involvement of p53 in cell differentiation and development
Almog, N., & Rotter, V. (1997) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(97)00012-7 · Cited by 162
Saleh, M. N., Patel, M. R., Bauer, T. M., Goel, S., Falchook, G. S., Shapiro, G. I., Chung, K. Y., Infante, J. R., Conry, R. M., Rabinowits, G., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0715 · Cited by 159
Regulation of ES cell differentiation by functional and conformational modulation of p53
Sabapathy, K. (1997) · The EMBO Journal · doi:10.1093/emboj/16.20.6217 · Cited by 159
“Furthermore, mice lacking mdm2 die due to presence of p53 (de Oca Luna et al., 1995; Jones et al., 1995).”
BackgroundSynergistic activation of p53 by inhibition of MDM2 expression and DNA damage
Chen, L., Agrawal, S., Zhou, W., Zhang, R., & Chen, J. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.1.195 · Cited by 159
A TSG101/MDM2 regulatory loop modulates MDM2 degradation and MDM2/p53 feedback control
Li, L., Liao, J., Ruland, J., Mak, T. W., & Cohen, S. N. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.98.4.1619 · Cited by 159
Regulation of p53 by the Ubiquitin-conjugating Enzymes UbcH5B/C in Vivo
Saville, M. K., Sparks, A., Xirodimas, D. P., Wardrop, J., Stevenson, L. F., Bourdon, J.-C., Woods, Y. L., & Lane, D. P. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m403362200 · Cited by 158
Current developments of targeting the p53 signaling pathway for cancer treatment
Huang, J. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107720 · Cited by 157
Chao, C. C. ‐. (2014) · Clinica Chimica Acta · doi:10.1016/j.cca.2014.08.015 · Cited by 167
p53 is balancing development, differentiation and de-differentiation to assure cancer prevention
Molchadsky, A., Rivlin, N., Brosh, R., Rotter, V., & Sarig, R. (2010) · Carcinogenesis · doi:10.1093/carcin/bgq101 · Cited by 156
p53 Stabilization and Accumulation Induced by Human Vaccinia-Related Kinase 1
Vega, F. M., Sevilla, A., & Lazo, P. A. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.23.10366-10380.2004 · Cited by 156
Synergistic roles of Mdm2 and Mdm4 for p53 inhibition in central nervous system development
Xiong, S., Van Pelt, C. S., Elizondo-Fraire, A. C., Liu, G., & Lozano, G. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0508500103 · Cited by 155
Self-citationDoes p53 affect organismal aging?
Donehower, L. A. (2002) · Journal of Cellular Physiology · doi:10.1002/jcp.10104 · Cited by 155
“This is consistent with earlier studies indicating that C-terminal fragments or peptides of p53 could augment wild type p53 activity for DNA binding and transactivation function (Muller-Tiemann et al., 1998; Selivanova et al., 1999).”
ResultChen, J., Ng, S. M., Chang, C., Zhang, Z., Bourdon, J.-C., Lane, D. P., & Peng, J. (2009) · Genes & Development · doi:10.1101/gad.1761609 · Cited by 154
“Further studies will be required to fully understand how the selectivity is achieved. p53 is usually kept at a low level in normal cells (Montes de Oca et al. 1995; Langheinrich et al. 2002).”
Complications associated with genetic background effects in research using knockout mice
Phillips, T. J., Hen, R., & Crabbe, J. C. (1999) · Psychopharmacology · doi:10.1007/s002130051128 · Cited by 161
Proteasome activator PA28γ regulates p53 by enhancing its MDM2-mediated degradation
Zhang, Z., & Zhang, R. (2008) · The EMBO Journal · doi:10.1038/emboj.2008.25 · Cited by 153
“MDM2 knockout results in lethality early in development in mice (Jones et al, 1995; Montes de Oca Luna et al, 1995).”
BackgroundPhosphorylation of Serine 18 Regulates Distinct p53 Functions in Mice
Sluss, H. K., Armata, H., Gallant, J., & Jones, S. N. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.3.976-984.2004 · Cited by 152
“These findings suggest that p53Ser18 must be the key regulatory was partially compromised in our p53Ala18 model, it is clear from our data that ATM and ATR must rely upon targets other than serine 18 to fully regulate p53 activity in response to DNA damage and to suppress tumor formation.”
BackgroundMethodLindstroöm, M. S., Jin, A., Deisenroth, C., White Wolf, G., & Zhang, Y. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.01307-06 · Cited by 152
“Mice with targeted deletion of the Mdm2 gene die during early embryonic development, and this lethality can be rescued by concomitant deletion of p53, indicating that a major in vivo function of MDM2 is to keep p53 activity in check (27, 33).”
BackgroundTumor suppressor p53: regulation and function
Somasundaram, K. (2000) · Frontiers in bioscience · doi:10.2741/somasund · Cited by 174
Promoter specificity and stability control of the p53-related protein p73
Lee, C., & Thangue, N. B. L. (1999) · Oncogene · doi:10.1038/sj.onc.1202793 · Cited by 170
“Mice de®cient for mdm2 are not viable unless they also lack the p53 gene (Jones et al., 1995; de Oca Luna et al., 1995), suggesting that the regulation of p53 is an important physiological function of MDM2.”
Backgroundp53, Stem Cells, and Reprogramming: Tumor Suppression beyond Guarding the Genome
Spike, B. T., & Wahl, G. M. (2011) · Genes & Cancer · doi:10.1177/1947601911410224 · Cited by 135
Targeting MDM2-p53 Interaction for Cancer Therapy: Are We There Yet?
Nag, S., Zhang, X., Srivenugopal, K. S., Wang, M.-H., Wang, W., & Zhang, R. (2014) · Current Medicinal Chemistry · doi:10.2174/09298673113206660325 · Cited by 149
“The direct evidence for the crucial role of MDM2 in negatively regulating p53 comes from the fact that targeted deletion of the mdm2 gene in mice is embryonic lethal due to p53-mediated apoptosis, whereas simultaneous deletion of the TP53 gene rescues the lethality [35, 36].”
BackgroundApoptosis and protein expression after focal cerebral ischemia in rat
Li, Y., Chopp, M., Powers, C., & Jiang, N. (1997) · Brain Research · doi:10.1016/s0006-8993(97)00524-6 · Cited by 159
Tissue-specific differences of p53 inhibition by Mdm2 and Mdm4
Grier, J. D., Xiong, S., Elizondo-Fraire, A. C., Parant, J. M., & Lozano, G. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.26.1.192-198.2006 · Cited by 149
“previously described for an Mdm2 null allele (25).”
BackgroundMethodInfluentialSelf-citationBrown, D. R., Thomas, C. A., & Palit Deb, S. (1998) · The EMBO Journal · doi:10.1093/emboj/17.9.2513 · Cited by 148
“The human oncoprotein MDM2 arrests the cell cycle: elimination of its cell-cycle-inhibitory function induces tumorigenesis”
BackgroundStrategies for manipulating the p53 pathway in the treatment of human cancer
Hupp, T. R., Lane, D. P., & Ball, K. L. (2000) · Biochemical Journal · doi:10.1042/0264-6021:3520001 · Cited by 148
Pharmacologic Activation of p53 by Small-Molecule MDM2 Antagonists
Shen, H., & G. Maki, C. (2011) · Current Pharmaceutical Design · doi:10.2174/138161211795222603 · Cited by 147
“MDM2 gene knockout leads to early embryonic lethality in mice, a phenotype that could be rescued by simultaneous deletion of the p53 gene [20, 21].”
BackgroundRoles of Histone Deacetylases and Inhibitors in Anticancer Therapy
Verza, F. A., Das, U., Fachin, A. L., Dimmock, J. R., & Marins, M. (2020) · Cancers · doi:10.3390/cancers12061664 · Cited by 143
An E3 ligase guide to the galaxy of small-molecule-induced protein degradation
Jevtić, P., Haakonsen, D. L., & Rapé, M. (2021) · Cell Chemical Biology · doi:10.1016/j.chembiol.2021.04.002 · Cited by 143
Inappropriate p53 activation during development induces features of CHARGE syndrome
Van Nostrand, J. L., Brady, C. A., Jung, H., Fuentes, D. R., Kozak, M. M., Johnson, T. M., Lin, C.-Y., Lin, C.-J., Swiderski, D. L., Vogel, H., et al. (2014) · Nature · doi:10.1038/nature13585 · Cited by 143
Bu, P., Evrard, Y. A., Lozano, G., & Dent, S. Y. R. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.00066-07 · Cited by 144
“Genotyping for the p53 allele was performed as described previously (27).”
MethodSelf-citationp53 Accumulation, defective cell proliferation, and early embryonic lethality in mice lacking tsg101
Ruland, J., Sirard, C., Elia, A., MacPherson, D., Wakeham, A., Li, L., Luis de la Pompa, J., Cohen, S. N., & Mak, T. W. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.98.4.1859 · Cited by 145
p53 in embryonic development: maintaining a fine balance
Choi, J. M., & Donehower, L. A. (1999) · Cellular and Molecular Life Sciences · doi:10.1007/s000180050268 · Cited by 162
Alarcon, R. M., Koumenis, C., Geyer, R. K., Maki, C. G., & Giaccia, A. J. (1999) · PubMed · Cited by 170
Hdmx protein stability is regulated by the ubiquitin ligase activity of Mdm2
de Graaf, P., Little, N. A., Ramos, Y. F. M., Meulmeester, E., Letteboer, S. J. F., & Jochemsen, A. G. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m213034200 · Cited by 143
The loss of mdm2 induces p53 mediated apoptosis
de Rozìeres, S., Maya, R. B.-Y., Oren, M., & Lozano, G. (2000) · Oncogene · doi:10.1038/sj.onc.1203468 · Cited by 164
Self-citationAbbas, H. A., Maccio, D. R., Coskun, S., Jackson, J. G., Hazen, A. L., Sills, T. M., You, M. J., Hirschi, K. K., & Lozano, G. (2010) · Cell Stem Cell · doi:10.1016/j.stem.2010.09.013 · Cited by 142
“Genotyping was performed as previously described for p53515C (Liu et al., 2004), Mdm2 (Montes de Oca Luna et al., 1995), p16 (Sharpless et al., 2001), and p21 (Brugarolas et al., 1998).”
BackgroundMethodInfluentialSelf-citationKaelin, W. G. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.7.594 · Cited by 173
Cell Type- and Promoter-specific Roles of Ser18 Phosphorylation in Regulating p53 Responses
Chao, C., Hergenhahn, M., Kaeser, M. D., Wu, Z., Saito, S., Iggo, R., Hollstein, M., Appella, E., & Xu, Y. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m306938200 · Cited by 141
Chromatin-Bound MDM2 Regulates Serine Metabolism and Redox Homeostasis Independently of p53
Riscal, R., Schrepfer, E., Arena, G., Cissé, M. Y., Bellvert, F., Heuillet, M., Rambow, F., Bonneil, É., Sabourdy, F., Vincent, C., et al. (2016) · Molecular Cell · doi:10.1016/j.molcel.2016.04.033 · Cited by 149
“The critical role of MDM2 in p53 regulation was genetically demonstrated by the rescue of the embryonic lethality of Mdm2-deficient mice by the concomitant inactivation of p53 (Jones et al., 1995; Montes de Oca Luna et al., 1995).”
BackgroundThe Mdm2 Oncoprotein Interacts with the Cell Fate Regulator Numb
Juven-Gershon, T., Shifman, O., Unger, T., Elkeles, A., Haupt, Y., & Oren, M. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.7.3974 · Cited by 140
“The importance of this autoregulatory loop is highlighted by the observations that mice deficient in Mdm2 die early in development but that mice deficient for both p53 and Mdm2 develop rather normally and are viable (29, 43).”
BackgroundLiu, J., Zhang, C., Zhao, Y., & Feng, Z. (2017) · Journal of Cellular Biochemistry · doi:10.1002/jcb.25609 · Cited by 138
Apoptosis and expression of p53 response proteins and cyclin D1 after cortical impact in rat brain
Kaya, S. S., Mahmood, A., Li, Y., Yavuz, E., Goksel, M., & Chopp, M. (1999) · Brain Research · doi:10.1016/s0006-8993(98)01204-9 · Cited by 149
Liu, Y., Whelan, R. J., Pattnaik, B. R., Ludwig, K. D., Subudhi, E., Rowland, H., Claussen, N., Zucker, N. A., Uppal, S., Kushner, D. M., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0053178 · Cited by 139
An alternatively spliced HDM2 product increases p53 activity by inhibiting HDM2
Evans, S. C., Viswanathan, M., Grier, J. D., Narayana, M., El‐Naggar, A. K., & Lozano, G. (2001) · Oncogene · doi:10.1038/sj.onc.1204533 · Cited by 153
“At 24 h or after transfection, cells were washed in phosphate-bu ered saline (PBS) and ®xed in 95% ethanol/5% acetic acid for 5 min at 7208C. Cells were washed three times with PBS, blocked for 30 min at room temperature in 2% horse serum/PBS, and then incubated for 1 h at room temperature in SMP14 (1 : 1000) (Santa C…”
BackgroundMethodSelf-citationIntroduction: p53 – the first twenty years
Oren, M., & Rotter, V. (1999) · Cellular and Molecular Life Sciences · doi:10.1007/s000180050265 · Cited by 180
E3 ubiquitin ligase TRIM32 negatively regulates tumor suppressor p53 to promote tumorigenesis
Liu, J., Zhang, C., Wang, X. L., Ly, P., Белый, В. А., Xu-Monette, Z. Y., Young, K. H., Hu, W., & Feng, Z. (2014) · Cell Death and Differentiation · doi:10.1038/cdd.2014.121 · Cited by 147
Reactivation of p53: from peptides to small molecules
Brown, C. J., Cheok, C. F., Verma, C. S., & Lane, D. P. (2010) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2010.11.004 · Cited by 149
Pant, V., Xiong, S., Iwakuma, T., Quintás-Cardama, A., & Lozano, G. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1102241108 · Cited by 134
Self-citationToufektchan, E., & Toledo, F. (2018) · Cancers · doi:10.3390/cancers10050135 · Cited by 134
β-Arrestin 2 Functions as a G-Protein-coupled Receptor-activated Regulator of Oncoprotein Mdm2
Wang, P., Gao, H., Ni, Y., Wang, B., Wu, Y., Ji, L., Qin, L., Ma, L., & Pei, G. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210350200 · Cited by 134
TGF-β1–induced expression of human Mdm2 correlates with late-stage metastatic breast cancer
Araki, S., Eitel, J. A., Batuello, C. N., Bijangi-Vishehsaraei, K., Xie, X.-J., Danielpour, D., Pollok, K. E., Boothman, D. A., & Mayo, L. D. (2010) · Journal of Clinical Investigation · doi:10.1172/jci39194 · Cited by 133
“Furthermore, Mdm2–/– mice are embryonic lethal (12, 13).”
BackgroundAnti-apoptotic protein TCTP controls the stability of the tumor suppressor p53
Rho, S. B., Lee, J. H., Park, M. S., Byun, H., Kang, S., Seo, S., Kim, J., & Park, S. (2010) · FEBS Letters · doi:10.1016/j.febslet.2010.11.014 · Cited by 147
“This early lethal phenotype can be suppressed completely by simultaneous inactivation of p53, suggesting that the main function of Hdm2 in vivo is to regulate p53 [19].”
BackgroundWang, Y., Suh, Y.-A., Fuller, M. Y., Jackson, J. G., Xiong, S., Terzian, T., Quintás-Cardama, A., Bankson, J. A., El-Naggar, A. K., & Lozano, G. (2011) · Journal of Clinical Investigation · doi:10.1172/jci44504 · Cited by 131
Self-citationTsg101 Is Essential for Cell Growth, Proliferation, and Cell Survival of Embryonic and Adult Tissues
Wagner, K., Krempler, A., Qi, Y., Park, K.-R., Henry, M. D., Triplett, A. A., Riedlinger, G., Rucker, E. B., & Hennighausen, L. G. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.23.1.150-162.2003 · Cited by 134
“Given the suggested importance of Tsg101 as a key regulator of Mdm2, this rescue seemed to be marginal compared to that in Mdm2/ p53 double-mutant mice, where a knockout of p53 completely rescued embryonic death caused by Mdm2 deficiency (9, 21).”
ResultAttenuating the p53 Pathway in Human Cancers: Many Means to the Same End
Wasylishen, A. R., & Lozano, G. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026211 · Cited by 123
“Mdm2-null mice are early embryonic lethal, losing viability preimplantation (Jones et al. 1995; Montes de Oca Luna et al. 1995; Chavez-Reyes et al. 2003).”
BackgroundSelf-citationMdm2 Binds to Nbs1 at Sites of DNA Damage and Regulates Double Strand Break Repair
Alt, J. R., Bouska, A., Fernandez, M. R., Cerny, R. L., Xiao, H., & Eischen, C. M. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m413387200 · Cited by 131
Johnson, T. M., Hammond, E. M., Giaccia, A. J., & Attardi, L. D. (2005) · Nature Genetics · doi:10.1038/ng1498 · Cited by 161
“We anticipated the possibility that this mutant may result in embryonic lethality because of its inability to bind mdm2 and engineered the mutated locus such that expression of p53 QS is conditiona”
Mdm2 haplo‐insufficiency profoundly inhibits Myc‐induced lymphomagenesis
Alt, J. R., Greiner, T. C., Cleveland, J. L., & Eischen, C. M. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg133 · Cited by 129
The p53 pathway in hematopoiesis: lessons from mouse models, implications for humans
Pant, V., Quintás-Cardama, A., & Lozano, G. (2012) · Blood · doi:10.1182/blood-2012-05-356014 · Cited by 129
Self-citationGerety, S. S., & Wilkinson, D. G. (2010) · Developmental Biology · doi:10.1016/j.ydbio.2010.11.030 · Cited by 154
“It is not surprising that the mouse knock-out has speci fi c, extensive cell death (Jones et al., 1995; Montes de Oca Luna et al., 1995).”
Backgroundp53 regulates the cardiac transcriptome
Mak, T. W., Hauck, L., Grothe, D., & Billia, F. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1621436114 · Cited by 129
“Loss of Mdm2 in mice leads to death in embryogenesis through p53-induced apoptosis, which is prevented by p53 codeletion (6).”
BackgroundBanks, D., Wu, M., Higa, L. A., Gavrilova, N., Quan, J., Ye, T., Kobayashi, R., Sun, H., & Zhang, H. (2006) · Cell Cycle · doi:10.4161/cc.5.15.3150 · Cited by 127
New insights into p53 activation
Brooks, C. L., & Gu, W. (2010) · Cell Research · doi:10.1038/cr.2010.53 · Cited by 102
Classic and novel roles of p53: prospects for anticancer therapy
Fuster, J. J., Sanz-Gonzalez, S. M., Moll, U. M., & Andrés, V. (2007) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2007.03.002 · Cited by 141
“This regulatory pathway seems to be important in vivo, since p53 inactivation abrogates the early embryonic lethality caused in mouse by Mdm2 deficiency [14, 15].”
BackgroundCocompartmentalization of p53 and Mdm2 Is a Major Determinant for Mdm2-Mediated Degradation of p53
Xirodimas, D. P., Stephen, C. W., & Lane, D. P. (2001) · Experimental Cell Research · doi:10.1006/excr.2001.5314 · Cited by 150
Into the heart: The emerging role of the ubiquitin–proteasome system
Willis, M. S., & Patterson, C. (2006) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2006.07.015 · Cited by 138
The Oscar-worthy role of Myc in apoptosis
Meyer, N., Kim, S. S., & Penn, L. Z. (2006) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2006.07.011 · Cited by 158
“The mbryonic lethality of Mdm2−/− mice can be rescued when rossbred to p53−/− mice, demonstrating that the Mdm2−/− ice die in utero due to high levels of p53 [68].”
Background
Metadata
- Authors
- de Oca Luna, R. M., Wagner, D. S., & Lozano, G.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- Venue
- Nature
- Published
- 1995-11
- Volume
- 378
- Issue
- 6553
- Pages
- 203-206
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W1969044026
- Semantic Scholar
- e682601f6b2b8de8fa63cc39518a1461943483bc
- Cited by
- 1,420
- References
- 29
- Citations by year
- 2026: 10 · 2025: 24 · 2024: 31 · 2023: 30 · 2022: 31 · 2021: 32 · 2020: 49 · 2019: 29 · 2018: 32 · 2017: 49 · 2016: 63 · 2015: 44 · 2014: 67 · 2013: 37 · 2012: 63
- FWCI
- 15.76
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Heat shock proteins research
- Keywords
- p53, MDM2, embryonic lethality, p53-MDM2 interaction, tumor suppressor, sarcoma, homologous recombination, DNA repair
- MeSH terms
- Animals, Base Sequence, Cell Line, Crosses, Genetic, Female, Genes, Lethal, Heterozygote, Homozygote, Male, Mice, Inbred C57BL, Molecular Sequence Data, Nuclear Proteins, Proto-Oncogene Proteins, Tumor Suppressor Protein p53, Gene Deletion, DNA Primers, Mice, Proto-Oncogene Proteins c-mdm2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.